X0306 4 2020-03-17 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001253886 ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 2740 SAND HILL ROAD, SECOND FLOOR MENLO PARK CA 94025 1 0 0 0 Common Stock, $0.0001 par value 2020-03-17 4 P 0 100000 11.3965 A 6113134 I By: LVP2 Common Stock, $0.0001 par value 2020-03-17 4 P 0 8787 11.50 A 54348 D Common Stock, $0.0001 par value 2020-03-18 4 P 0 16213 11.0618 A 70561 D The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $11.35 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting, investment and dispositive power with respect to such securities. The Reporting Person (a member of the Issuer's board of directors) and Juliet Tammenoms Bakker are the managing members of LCP II. Each of LCP II, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $10.66 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. /s/ Patrick G. Enright 2020-03-19